Rodriguez J, Keating M J, O'Brien S, Champlin R E, Khouri I F
Department of Blood and Marrow Transplantation, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Br J Haematol. 2000 Sep;110(4):897-9. doi: 10.1046/j.1365-2141.2000.02295.x.
This study evaluated the efficacy of allogeneic bone marrow transplantation (AlloBMT) in eight patients who had chronic lymphocytic leukaemia (CLL) in Richter's transformation. Five patients were in resistant relapse and three others were in sensitive or untreated relapse. Three out of eight patients (38%) were alive and in remission at 14 months, 47 months and 67 months respectively. Two of these three patients, including one with an unrelated-donor transplant and a prior, unsuccessful autologous transplantation, received a non-myeloablative preparative regimen. These data suggest that, compared with conventional chemotherapy, AlloBMT improves the prognosis for patients with Richter's syndrome. Further study of a larger number of patients is needed to confirm these results.
本研究评估了异基因骨髓移植（AlloBMT）对8例处于Richter转化期的慢性淋巴细胞白血病（CLL）患者的疗效。5例患者处于耐药复发阶段，另外3例处于敏感或未治疗的复发阶段。8例患者中有3例（38%）分别在14个月、47个月和67个月时存活且处于缓解状态。这3例患者中的2例，包括1例接受非亲缘供者移植且之前自体移植未成功的患者，接受了非清髓性预处理方案。这些数据表明，与传统化疗相比，AlloBMT改善了Richter综合征患者的预后。需要对更多患者进行进一步研究以证实这些结果。
